[1] MEGWALU U C, MOON P K.Thyroid cancer incidence and mortality trends in the United States:2000-2018[J].Thyroid, 2022, 32(5):560-570.
[2] SIEGEL R L, MILLER K D, FUCHS H E, et al.Cancer statistics, 2022[J].CA Cancer J Clin, 2022, 72(1):7-33.
[3] DENG Y, LI H, WANG M, et al.Global burden of thyroid cancer from 1990 to 2017[J].JAMA Netw Open, 2020, 3(6):e208759.
[4] LI P, DING Y, LIU M, et al.Sex disparities in thyroid cancer:a SEER population study[J].Gland Surg, 2021, 10(12):3200-3210.
[5] DING J, WU W, FANG J, et al.Male sex is associated with aggressive behaviour and poor prognosis in Chinese papillary thyroid carcinoma[J].Sci Rep, 2020, 10(1):4141.
[6] AHN H Y, SONG R Y, AHN H S, et al.Expression of estrogen and progesterone receptors in papillary thyroid carcinoma in Korea[J].Cancer Res Treat, 2021, 53(4):1204-1212.
[7] LIU J, XU T, MA L, et al.Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J].Front Oncol, 2021, 11:593479.
[8] YI J W, KIM S J, KIM J K, et al.Upregulation of the ESR1 gene and ESR ratio(ESR1/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma:the impact of the estrogen receptor alpha/beta expression on clinical outcomes in papillary thyroid carcinoma patients[J].Ann Surg Oncol, 2017, 24(12):3754-3762.
[9] YANG S, GONG Z, LIU Z, et al.Differential effects of estrogen receptor alpha and beta on endogenous ligands of peroxisome proliferator-activated receptor gamma in papillary thyroid cancer[J].Front Endocrinol(Lausanne), 2021, 12:708248.
[10] CHENG L, LI J, HAN Y, et al.PES1 promotes breast cancer by differentially regulating ERalpha and ERbeta[J].J Clin Invest, 2012, 122(8):2857-2870.
[11] QIU Y B, LIAO L Y, JIANG R, et al.PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERalpha/ERbeta protein ratio[J].Sci Rep, 2019, 9(1):1032.
[12] ZOU Y, WANG D, CHENG X, et al.Reference intervals for thyroid-associated hormones and the prevalence of thyroid diseases in the Chinese population[J].Ann Lab Med, 2021, 41(1):77-85.
[13] ARAFAH B M.Increased need for thyroxine in women with hypothyroidism during estrogen therapy[J].N Engl J Med, 2001, 344(23):1743-1749.
[14] SUZUKI S, MIDORIKAWA S, MATSUZUKA T, et al.Prevalence and characterization of thyroid hemiagenesis in Japan:the fukushima health management survey[J].Thyroid, 2017, 27(8):1011-1016.
[15] GRASSI E S, GHIANDAI V, PERSANI L.Thyroid cancer stem-like cells:from microenvironmental niches to therapeutic strategies[J].J Clin Med, 2021, 10(7):1455.
[16] CHEN D, TAN Y, LI Z, et al.Organoid cultures derived from patients with papillary thyroid cancer[J].J Clin Endocrinol Metab, 2021, 106(5):1410-1426.
[17] XU S, CHEN G, PENG W, et al.Oestrogen action on thyroid progenitor cells:relevant for the pathogenesis of thyroid nodules?[J].J Endocrinol, 2013, 218(1):125-133.
[18] LI M, CHAI H F, PENG F, et al.Estrogen receptor beta upregulated by lncRNA-H19 to promote cancer stem-like properties in papillary thyroid carcinoma[J].Cell Death Dis, 2018, 9(11):1120.
[19] KOCHMAN J, JAKUBCZYK K, BARGIEL P, et al.The influence of oxidative stress on thyroid diseases[J].Antioxidants(Basel), 2021, 10(9):1442.
[20] AMEZIANE-EL-HASSANI R, SCHLUMBERGER M, DUPUY C.NADPH oxidases:new actors in thyroid cancer?[J].Nat Rev Endocrinol, 2016, 12(8):485-494.
[21] STEPNIAK J, LEWINSKI A, KARBOWNIK-LEWINSKA M.Sexual dimorphism of NADPH oxidase/H(2)O(2) system in rat thyroid cells; effect of exogenous 17beta-estradiol[J].Int J Mol Sci, 2018, 19(12):4063.
[22] METERE A, FREZZOTTI F, GRAVES C E, et al.A possible role for selenoprotein glutathione peroxidase(GPx1) and thioredoxin reductases(TrxR1) in thyroid cancer:our experience in thyroid surgery[J].Cancer Cell Int, 2018, 18:7.
[23] FORTUNATO R S, BRAGA W M, ORTENZI V H, et al.Sexual dimorphism of thyroid reactive oxygen species production due to higher NADPH oxidase 4 expression in female thyroid glands[J].Thyroid, 2013, 23(1):111-119.
[24] RAJORIA S, SURIANO R, SHANMUGAM A, et al.Metastatic phenotype is regulated by estrogen in thyroid cells[J].Thyroid, 2010, 20(1):33-41.
[25] KAMAT A, RAJORIA S, GEORGE A, et al.Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways[J].Arch Otolaryngol Head Neck Surg, 2011, 137(11):1146-1153.
[26] DONG W W, LI J, LI J, et al.Reduced expression of oestrogen receptor-beta is associated with tumour invasion and metastasis in oestrogen receptor-alpha-negative human papillary thyroid carcinoma[J].Int J Exp Pathol, 2018, 99(1):15-21.
[27] LI L, LI H, ZHANG J, et al.Bisphenol A at a human exposed level can promote epithelial-mesenchymal transition in papillary thyroid carcinoma harbouring BRAF(V600E) mutation[J].J Cell Mol Med, 2021, 25(3):1739-1749.
[28] WEI W, HARDIN H, LUO Q Y.Targeting autophagy in thyroid cancers[J].Endocr Relat Cancer, 2019, 26(4):R181-R194.
[29] FAN D, LIU S Y, VAN HASSELT C A, et al.Estrogen receptor alpha induces prosurvival autophagy in papillary thyroid cancer via stimulating reactive oxygen species and extracellular signal regulated kinases[J].J Clin Endocrinol Metab, 2015, 100(4):E561-E571.
[30] ZHOU H, XIE X, CHEN Y, et al.Chaperone-mediated autophagy governs progression of papillary thyroid carcinoma via PPARgamma-SDF1/CXCR4 signaling[J].J Clin Endocrinol Metab, 2020, 105(10):dgaa366.
[31] CHOU C K, CHI S Y, CHOU F F, et al.Aberrant expression of androgen receptor associated with high cancer risk and extrathyroidal extension in papillary thyroid carcinoma[J].Cancers(Basel), 2020, 12(5):1109.
[32] THORSSON V, GIBBS D L, BROWN S D, et al.The immune landscape of cancer[J].Immunity, 2018, 48(4):812-830.
[33] O'CONNELL T J, DADAFARIN S, JONES M, et al.Androgen activity is associated with PD-L1 downregulation in thyroid cancer[J].Front Cell Dev Biol, 2021, 9:663130.
[34] JONES M E, O'CONNELL T J, ZHAO H, et al.Androgen receptor activation decreases proliferation in thyroid cancer cells[J/OL].J Cell Biochem, 2021.Doi:10.1002/jcb.29934.
[35] KWON H, SCHAFER J M, SONG N J, et al.Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer[J].Sci Immunol, 2022, 7(73):q2630.
[36] ZAHEDI A, BONDAZ L, RAJARAMAN M, et al.Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation[J].Thyroid, 2020, 30(6):871-877.
[37] WANG F, ZHAO S, SHEN X, et al.BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer[J].J Clin Oncol, 2018, 36(27):2787-2795.
[38] ZHU J, HUANG R, YU P, et al.Male gender is associated with lymph node metastasis but not with recurrence in papillary thyroid carcinoma[J].Int J Endocrinol, 2022, 2022:3534783.
[39] KIM H, KWON H, MOON B I.Predictors of recurrence in patients with papillary thyroid carcinoma:does male sex matter?[J].Cancers(Basel), 2022, 14(8):1896.
[40] PARK J, KIM K, LIM D J, et al.Male sex is not an independent risk factor for recurrence of differentiated thyroid cancer:a propensity score-matching study[J].Sci Rep, 2021, 11(1):14908.
[41] YOSHIMURA M, HERSHMAN J M.Thyrotropic action of human chorionic gonadotropin[J].Thyroid, 1995, 5(5):425-434.
[42] HERSHMAN J M.Human chorionic gonadotropin and the thyroid:hyperemesis gravidarum and trophoblastic tumors[J].Thyroid, 1999, 9(7):653-657.
[43] SHINDO H, AMINO N, ITO Y, et al.Papillary thyroid microcarcinoma might progress during pregnancy[J].Thyroid, 2014, 24(5):840-844.
[44] SHELLY S, BOAZ M, ORBACH H.Prolactin and autoimmunity[J].Autoimmun Rev, 2012, 11(6-7):A465-A470.
[45] SAYKI A M, SAHIN M, TOPALOGLU O, et al.Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma[J].Clin Endocrinol(Oxf), 2013, 79(6):882-886.
[46] PILLI T, CARDINALE S, DALMIGLIO C, et al.Autoimmune thyroid diseases are more common in patients with prolactinomas:a retrospective case-control study in an Italian cohort[J].J Endocrinol Invest, 2019, 42(6):693-698.
[47] LINDQUIST S, KJAER S K, ALBIERI V, et al.Fertility drugs and incidence of thyroid cancer in a Danish nationwide cohort of 146024 infertile women[J].Hum Reprod, 2022, 37(4):838-847.
[48] SCHUBART J R, ELIASSEN A H, SCHILLING A, et al.Reproductive factors and risk of thyroid cancer in women:an analysis in the nurses' health study II[J].Womens Health Issues, 2021, 31(5):494-502.
[49] WANG M, GONG W W, HE Q F, et al.Menstrual, reproductive and hormonal factors and thyroid cancer:a hospital-based case-control study in China[J].BMC Womens Health, 2021, 21(1):13.
[50] 龙娜, 孙汝亮, 麦慧芬, 等.雌、孕激素受体及端粒酶在种植窗期子宫内膜中表达的研究[J].现代医学, 2021, 49(7):756-760.
[51] ITO Y, MIYAUCHI A, KUDO T, et al.Effects of pregnancy on papillary microcarcinomas of the thyroid re-evaluated in the entire patient series at Kuma Hospital[J].Thyroid, 2016, 26(1):156-160.
[52] VANNUCCHI G, PERRINO M, ROSSI S, et al.Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy[J].Eur J Endocrinol, 2010, 162(1):145-151.
[53] HIRSCH D, LEVY S, TSVETOV G, et al.Impact of pregnancy on outcome and prognosis of survivors of papillary thyroid cancer[J].Thyroid, 2010, 20(10):1179-1185.
[54] DRIOUICH Y, HARAJ N E, EL A S, et al.Impact of pregnancy on papillary thyroid carcinoma prognosis[J].Pan Afr Med J, 2021, 38:261.
[55] XI C, ZHANG Q, SONG H J, et al.Pregnancy does not affect the prognoses of differentiated thyroid cancer patients with lung metastases[J].J Clin Endocrinol Metab, 2021, 106(8):e3185-e3197.
[56] WILSON M A, BUETOW K H.Novel mechanisms of cancer emerge when accounting for sex as a biological variable[J].Cancer Res, 2020, 80(1):27-29.
[57] CACERES A, JENE A, ESKO T, et al.Extreme downregulation of chromosome Y and cancer risk in men[J].J Natl Cancer Inst, 2020, 112(9):913-920.
[58] DUNFORD A, WEINSTOCK D M, SAVOVA V, et al.Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias[J].Nat Genet, 2017, 49(1):10-16.
[59] TRICARICO R, NICOLAS E, HALL M J, et al.X-and Y-linked chromatin-modifying genes as regulators of sex-specific cancer incidence and prognosis[J].Clin Cancer Res, 2020, 26(21):5567-5578.
[60] SOUSA A, FERREIRA M, OLIVEIRA C, et al.Gender differential transcriptome in gastric and thyroid cancers[J].Front Genet, 2020, 11:808.
[61] QIU W, WU X, SHI H, et al.ASF1B:a possible prognostic marker, therapeutic target, and predictor of immunotherapy in male thyroid carcinoma[J].Front Oncol, 2022, 12:678025. |
